Autonomix Secures U.S. Patent for Overactive Bladder Platform, Expanding into $3B+ Urology Market
AMIX sits 38% above its 52-week low of $4.204.
Summary
Autonomix Medical has been granted U.S. Patent No. 12,611,134 for a catheter-based system that maps nerve activity, delivers targeted therapy, and verifies treatment effect for overactive bladder (OAB). The patent expands the company's neural sensing platform into a large urology market affecting an estimated 37 million Americans. This follows a series of positive developments: a reverse stock split in June that regained Nasdaq compliance, and a $2.6M warrant inducement deal yesterday. The IP portfolio now stands at 112 issued or pending applications worldwide, with expirations into the late 2030s, supporting multi-organ scalability. The technology offers a potential alternative to chronic drug therapy or implanted stimulators, with a 'Sense. Treat. Verify.' workflow that could enable precise, personalized treatment.
At the time of this announcement, AMIX was trading at $5.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8M. The 52-week trading range was $4.20 to $55.44. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.